Communications publiées lors de congrès ou colloques nationaux et internationaux (22)
9.
Bourgeois, P., Awada, A., Cornez, N., Mccabe, S., Gil, T., Branle, F., de Valeriola, D., Di Leo, A., Palmer, P., Piccart-Gebhart, M., & Fruhling, J. (2000). 99mTc-MIBI scintigraphies for the pharmacodynamic evaluation of R101933: A new inhibitor of the MDR-1 P-glycoprotein (PgP). Eur J Nucl Med. Vol. 27 (p. 8) (2000).10.
Awada, A., Bleiberg, H., Gil, T., Di Leo, A., Geurs, F., de Valeriola, D., Mc Cabe, S., Palmer, P., Woestenborghs, R., Piccart-Gebhart, M., et al. (1999). Oral R101933, an inhibitor of MDR1 P-glyco-protein does not significantly after the pharmacokinetics and pharmacodynamics of Paclitaxel. Proceedings of the American Association for Cancer Research. Vol. 40 (p. 663) (1999).11.
Awada, A., Bourgeois, P., Cornez, N., Bleiberg, H., Mccabe, S., Gil, T., Lehmann, F., de Valeriola, D., Di Leo, A., Piccart-Gebhart, M., et al. (1999). A clinical pharmacodynamic (Pd) and pharmacokinetic (Pk) phase I study of I.V. R101933, an inhibitor of MDR1 P-glycoprotein (PgP) given alone and in combination with Taxol in patients with solid tumors. Clinical Cancer Research. Vol. 5 (p. 3833) (1999).12.
Awada, A., de Valeriola, D., Gil, T., Kerger, J., Selleslags, J., Van Vreckem, A., Brassine, C., Hennebert, P., Riva, A., Piccart-Gebhart, M., et al. (1998). Influence of the cytoprotective agent Amifostine on toxicity and pharmacokinetics (PK) of Docetaxel (D) in metastasic breast cancer (MBC): A feasibility study of the EORTC-Investigational Drug Branch for Breast Cancer. Proceedings of the 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy. Vol. 55 (Juin 1998: Amsterdam, The Nederlands).13.
de Valeriola, D., Awada, A., Van Vreckem, A., Habboubi, N., Riva, A., & Piccart-Gebhart, M. (1998). Influence of amifostine (A) on the toxicity and pharmacokinetics (PK) of docetaxel (D) in breast cancer patients: An EORTC-IDBBC study. European Journal of Cancer 1st European Breast Cancer Conference(Septembre 1998: Florence, Italy)14.
Awada, A., Cornez, N., de Valeriola, D., Gil, T., Van Vreckem, A., Bartholomeus, S., Selleslags, J., Piccart-Gebhart, M., et al. (1997). Docetaxel in combination with Amifostine (A) in metastatic breast cancer (MBC): A feasability and pharmacokinetic study of the EORTC-investigational drug branch for breast cancer (IDBBC). Proceedings of the First International Symposium on Hematoxicology in New Drug Development (Juin 1997: Lugano, Switzerland)15.
Awada, A., de Valeriola, D., Cornez, N., Kerger, J., Van Vreckem, A., Bartholomeus, S., Selleslags, J., Piccart-Gebhart, M., et al. (1997). Docetaxel in combination with Amifostine (A) in metastatic breast cancer (MBC): A feasability and pharmacokinetic study of the EORTC-investigational drug branch for breast cancer (IDBBC). European Journal of Cancer. Vol. 33 (p. 159) (1997).16.
Piccart-Gebhart, M., Awada, A., Hamilton, A., Biganzoli, L., de Valeriola, D., & Di Leo, A. (1997). New drugs and new strategies for women with breast cancer. European Journal Cancer. Vol. 33 (pp. 216-217) (1997).17.
Van Den Neste, E., Kerger, J., de Valeriola, D., Bleiberg, H., Awada, A., Geurs, F., Piccart-Gebhart, M., et al. (1996). Phase I clinical study of Docetaxel (TXT) in combination with continuous infusion (CI) Fluorouracil (5-FU) in patients (pts) with advanced solid tumors. Proceedings of the American Association for Cancer Research. Vol. 37 (p. 168) (1996: Washington, Etats-Unis).18.
de Valeriola, D., Brassine, C., Lucas, C., Tueni, E., Awada, A., Parmentier, N., Bleiberg, H., & Piccart-Gebhart, M. (1995). Lack of interference of S9788 with the pharmacokinetic of adriamycin. Proceedings of the American Association for Cancer Research. Vol. 36 (p. 234) (Mars 1995: Toronto, Canada).19.
Luce, S., Awada, A., Gil, T., Kerger, J., de Valeriola, D., Bartholomeus, S., Parmentier, N., Bleiberg, H., Gérard, B., & Piccart-Gebhart, M. (1993). Etude de phase 1 d'un nouvel agent réverseur de la résistance multidrogue, le S9788 administré seul et en asociation avec l'adriamycine. Proceedings du 13è Forum de Cancérologie (1993: Paris, France)20.
Tomiak, E., Kerger, J., Lips, S., de Valeriola, D., Awada, A., Ravoet, C., Auzannet, V., Le Bail, N., Bayssas, M., & Piccart-Gebhart, M. (1992). Unexpected pleural changes observed in patients treated with Taxotere (RP 56976) : A new drug toxicity ? Proceeding of the Annals of Oncology. Vol. 3 (p. 58) (7-10 novembre 1992: Lyon, France).